TQB2440 Biosimilar Shows Promise as Affordable HER2-Positive Breast Cancer Treatment Option

Is TQB2440 the Affordable Alternative for HER2-Positive Breast Cancer?

Chinese biosimilar TQB2440 has demonstrated equivalent efficacy to reference pertuzumab in a pivotal phase III trial for HER2-positive early breast cancer, researchers report. The study, involving 412 patients across 56 centers in China, showed comparable total pathological complete response (tpCR) rates of 58.9% for TQB2440 versus 58.1% for reference pertuzumab, with the 90% confidence interval falling entirely within prespecified equivalence margins of 0.76-1.32.

What Is the Study's Background and Context?

The double-blind, randomized trial represents a significant advancement for patients with HER2-positive breast cancer, a particularly aggressive subtype affecting 15-20% of breast cancer patients worldwide. Dual HER2 inhibition with pertuzumab, trastuzumab, and chemotherapy (TPC) has become standard treatment following the landmark NeoSphere and APHINITY trials, but the high cost of pertuzumab—accounting for approximately 80% of the total TPC treatment cost—has limited access for many patients globally. In some countries, lack of reimbursement for pertuzumab has placed substantial economic burdens on both patients and healthcare systems, creating treatment disparities despite the regimen's proven efficacy. The development of TQB2440 addresses this critical need for more affordable treatment options that maintain clinical efficacy and safety.

How Was the Clinical Trial Designed and Assessed?

The study specifically enrolled patients with estrogen receptor/progesterone receptor-negative, HER2-positive early or locally advanced breast cancer, focusing on a homogeneous population most likely to benefit from TPC therapy. Patients received either TQB2440 or reference pertuzumab combined with trastuzumab and docetaxel for four neoadjuvant cycles, followed by surgery and adjuvant therapy. Beyond the primary endpoint of tpCR, secondary endpoints including investigator-assessed tpCR, breast pathological complete response (bpCR), breast-conserving surgery rate, and objective response rate also showed comparable results between the two treatment arms. "The robust study design and comprehensive endpoint assessment provide strong evidence for the biosimilarity of TQB2440 to reference pertuzumab," noted investigators involved in the trial.

Safety profiles were similarly consistent between the two products. Treatment-emergent adverse events occurred in 99.5% of patients receiving TQB2440 and 100% of those receiving reference pertuzumab, with grade ≥3 events in 79.7% and 81.4% of patients, respectively. The most common severe adverse events in both groups were decreased neutrophil and white blood cell counts. Importantly, cardiotoxicity—a concern with HER2-targeted therapies—occurred at comparable rates: 1.9% with TQB2440 versus 1.5% with reference pertuzumab. Pharmacokinetic and immunogenicity assessments further confirmed biosimilarity, with anti-drug antibodies detected in just 2.0% of TQB2440 patients and 1.5% of reference pertuzumab patients.

What Are the Market Implications of This Biosimilar?

The market implications of this successful phase III trial extend beyond China. Biosimilars typically enter markets at 69-90% of reference product prices in China and 70-85% in other countries, representing significant potential cost savings. "Biosimilars have demonstrated their ability to expand patient access while maintaining quality of care," said one market analyst. "The positive results for TQB2440 could significantly impact treatment accessibility for HER2-positive breast cancer patients who currently face financial barriers to optimal therapy." Experience with other oncology biosimilars has shown that their introduction often leads to increased overall consumption of the therapeutic class, suggesting more patients receive appropriate treatment when more affordable options become available.

What Does the Future Hold for TQB2440 and Biosimilars?

Looking ahead, long-term follow-up data will be crucial to confirm TQB2440's sustained efficacy and safety profile, particularly regarding cardiotoxicity concerns. The study authors acknowledge certain limitations, including the selective patient population (ER/PgR-negative only) and the need for extended observation periods. Future research may explore TQB2440's application in broader patient populations, including those with ER-positive, HER2-positive disease. Regulatory submissions based on these phase III results are anticipated, with potential approvals representing another step toward expanding global access to this important therapeutic approach.

Industry Context: This trial exemplifies the growing importance of biosimilars in oncology, where high-cost targeted therapies have created significant treatment disparities worldwide. As patents expire on original biologics, well-designed equivalence studies like this one provide the scientific foundation for more affordable alternatives. The biosimilar development pathway has matured considerably, with regulatory agencies establishing clear frameworks for demonstrating biosimilarity. For pharmaceutical companies, biosimilars represent both competitive challenges to established revenue streams and opportunities to expand market reach through more accessible pricing. Healthcare systems increasingly view biosimilars as essential tools for sustainable cancer care delivery, balancing innovation with affordability in an era of rapidly expanding therapeutic options.

Summary

A pivotal phase III clinical trial conducted across 56 centers in China has demonstrated that the biosimilar TQB2440 is equivalent to reference pertuzumab in treating HER2-positive early breast cancer. The randomized, double-blind study enrolled 412 patients with estrogen receptor/progesterone receptor-negative, HER2-positive early or locally advanced breast cancer. Results showed comparable total pathological complete response rates of 58.9% for TQB2440 versus 58.1% for reference pertuzumab, with confidence intervals meeting prespecified equivalence margins. Safety profiles were similarly consistent between both treatments, with comparable rates of treatment-emergent adverse events and cardiotoxicity. The development of TQB2440 addresses a critical need for more affordable treatment options, as pertuzumab currently accounts for approximately 80% of total treatment costs in the standard dual HER2 inhibition regimen. Biosimilars typically enter markets at significantly reduced prices compared to reference products, potentially expanding patient access to optimal therapy. The study's positive results could have substantial implications for treatment accessibility for HER2-positive breast cancer patients who face financial barriers to care. Long-term follow-up data will be essential to confirm sustained efficacy and safety, and regulatory submissions based on these phase III results are anticipated. This trial exemplifies the growing importance of biosimilars in oncology as a means of balancing therapeutic innovation with healthcare affordability.